David T. Rubin to Pyrroles
This is a "connection" page, showing publications David T. Rubin has written about Pyrroles.
Connection Strength
2.507
-
Real-World Experience with Tofacitinib in IBD at a Tertiary Center. Dig Dis Sci. 2019 07; 64(7):1945-1951.
Score: 0.598
-
Emerging Therapies for Inflammatory Bowel Disease. Adv Ther. 2018 11; 35(11):1746-1762.
Score: 0.587
-
The use of tofacitinib in the treatment of inflammatory bowel disease. Immunotherapy. 2018 08; 10(10):837-849.
Score: 0.566
-
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(3):302-310.
Score: 0.180
-
Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway. Am J Physiol Gastrointest Liver Physiol. 2019 06 01; 316(6):G774-G784.
Score: 0.151
-
The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know? Gastrointest Endosc Clin N Am. 2019 Jul; 29(3):405-419.
Score: 0.151
-
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies. J Crohns Colitis. 2018 Jan 24; 12(2):145-156.
Score: 0.139
-
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis. 2023 09 01; 29(9):1370-1379.
Score: 0.051
-
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
Score: 0.042
-
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1592-1601.e3.
Score: 0.041